Evidence map›Paper›PMID 30363462›Full record

ReviewTranslational andrology and urology2018

Prostate imaging features that indicate benign or malignant pathology on biopsy.

Catherine Elizabeth Lovegrove, Mudit Matanhelia, Jagpal Randeva, David Eldred-Evans, Henry Tam, Saiful Miah, Mathias Winkler, Hashim U Ahmed, Taimur T Shah

Open access · hybridAbstract readReview
In one paragraph

Review in Translational andrology and urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Radiology of fibrosis part III: genitourinary system.Journal of translational medicine · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. MR fingerprinting of the prostate.Magma (New York, N.Y.) · 2022
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. A Pilot Study ofFrontiers in oncology · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Catherine Elizabeth LovegroveDivision of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
Mudit MatanheliaDivision of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
Jagpal RandevaDivision of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
David Eldred-EvansDivision of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
Henry TamDivision of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
Saiful MiahDivision of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
Mathias WinklerDivision of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
Hashim U AhmedDivision of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
Taimur T ShahDivision of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
Charing Cross Hospital · GBImperial College Healthcare NHS Trust · GBImperial College London · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Accurate diagnosis of clinically significant prostate cancer is essential in identifying patients who should be offered treatment with curative intent. Modifications to the Gleason grading system in recent years show that accurate grading and reporting at needle biopsy can improve identification of clinically significant prostate cancers. Extracapsular extension of prostate cancer has been demonstrated to be an adverse prognostic factor with greater risk of metastatic spread than organ-confined disease. Tumor volume may be an independent prognostic factor and should be considered in conjunction with other factors. Multi-parametric magnetic resonance imaging (MP-MRI) has become an increasingly important tool in the diagnosis and characterization of prostate cancer. MP-MRI allows T2-weighted (T2W) anatomical imaging to be combined with functional and physiological assessment. Diffusion-weighted imaging (DWI) has shown greater sensitivity, specificity and negative predictive value compared to prostate specific antigen (PSA) testing and T2W imaging alone and has a more positive correlation with Gleason score and tumour volume. Dynamic gadolinium contrast-enhanced (DCE) imaging can exhibit difficulties in distinguishing prostatitis from malignancy in the peripheral zone, and between benign prostatic hyperplasia (BPH) and malignancies in the transition zone (TZ). Computer aided diagnosis utilizes software to aid radiologists in detecting and diagnosing abnormalities from diagnostic imaging. New techniques of quantitative MRI, such as VERDICT MRI use tissue-specific factors to delineate different cellular and microstructural phenotypes, characterizing tissue properties with greater detail. Proton MR spectroscopic imaging (MRSI) is a more technically challenging imaging modality than DCE and DWI MRI. Over the last decade, choline and prostate-specific membrane antigen (PSMA) positron emission tomography (PET) have developed as better tools for staging than conventional imaging. While hyperpolarized MRI shows promise in improving the imaging and differentiation of benign and malignant lesions there is further work required. Accurate reading and interpretation of diagnostic investigations is key to accurate identification of abnormal areas requiring biopsy, sparing those in whom benign or indolent disease can be managed by non-invasive means. Embracing and advancing existing technologies is essential in furthering this process.

Indexed as

benignimagingmagnetic resonance imaging (MRI)malignantparametricProstatequalitativequantitative

Identifiers

PMID30363462
PMCPMC6178322
OpenAlexW2884277086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.